Showing 1,841 - 1,860 results of 4,639 for search 'significantly ((((lower decrease) OR (teer decrease))) OR (linear decrease))', query time: 0.35s Refine Results
  1. 1841

    Gas-Phase Molecular Structure of 1‑Chlorosilatrane: Electron Diffraction Study and Assignment of Photoelectron Spectrum by Elena F. Belogolova (2025418)

    Published 2025
    “…This result shows that the Si←N bond length in 1-halosilatranes decreases when the halogen is replaced by an atom that forms a weaker bond with Si, rather than by a more electronegative atom. …”
  2. 1842

    Theoretical framework. by Dinku Mechal (21273002)

    Published 2025
    “…For quantitative part, pretested a self-administered five-point Likert scale questionnaire was used and analyzed using SPSS® -version 26. Assumptions of linear multivariate regression were checked and the level of significance determined at a 95% CI and p-value <0.05. …”
  3. 1843

    Supplementary file survey questioner annex. by Dinku Mechal (21273002)

    Published 2025
    “…For quantitative part, pretested a self-administered five-point Likert scale questionnaire was used and analyzed using SPSS® -version 26. Assumptions of linear multivariate regression were checked and the level of significance determined at a 95% CI and p-value <0.05. …”
  4. 1844

    Primers for quantitative real-time PCR. by Ya-nan Hu (12508990)

    Published 2024
    “…However, LDLR protein levels in the cell lysate of both the Gly343Ser and Ala627Thr variants groups were significantly lower than those in the wild-type group. …”
  5. 1845

    Descriptive data for the pBT-child dyads. by Madalina Ciobanu (2504683)

    Published 2025
    “…<div><p>Autism spectrum disorder (ASD) is a condition with growing prevalence that results in significant healthcare spending, reduced parent income, high levels of family stress, and decreased quality of life (QoL). …”
  6. 1846

    CFQL-2 descriptive statistics. by Madalina Ciobanu (2504683)

    Published 2025
    “…<div><p>Autism spectrum disorder (ASD) is a condition with growing prevalence that results in significant healthcare spending, reduced parent income, high levels of family stress, and decreased quality of life (QoL). …”
  7. 1847

    O<sub>2</sub> concentration under different conditions. by Zihao Chai (20521844)

    Published 2025
    “…Regarding the oxygen consumption activation energy, the primary oxidation process exhibited lower values in the first and second stages, but in the third stage, the secondary oxidation process at 25 mL/min and 100 mL/min air flow had lower oxygen consumption activation energy, while at 50 mL/min and 200 mL/min air flow, the primary oxidation process had lower oxygen consumption activation energy. …”
  8. 1848

    This is the paper’s data. by Zihao Chai (20521844)

    Published 2025
    “…Regarding the oxygen consumption activation energy, the primary oxidation process exhibited lower values in the first and second stages, but in the third stage, the secondary oxidation process at 25 mL/min and 100 mL/min air flow had lower oxygen consumption activation energy, while at 50 mL/min and 200 mL/min air flow, the primary oxidation process had lower oxygen consumption activation energy. …”
  9. 1849

    O<sub>2</sub> concentration under different conditions. by Zihao Chai (20521844)

    Published 2025
    “…Regarding the oxygen consumption activation energy, the primary oxidation process exhibited lower values in the first and second stages, but in the third stage, the secondary oxidation process at 25 mL/min and 100 mL/min air flow had lower oxygen consumption activation energy, while at 50 mL/min and 200 mL/min air flow, the primary oxidation process had lower oxygen consumption activation energy. …”
  10. 1850
  11. 1851
  12. 1852
  13. 1853
  14. 1854
  15. 1855
  16. 1856
  17. 1857
  18. 1858
  19. 1859

    Participant flow (CONSORT diagram). by David J. Diemert (8135568)

    Published 2024
    “…Peak anti-<i>Na</i>-GST-1 IgG levels were observed between 2 and 4 weeks following the third dose, regardless of <i>Na</i>-GST-1 formulation. IgG levels decreased but remained significantly above baseline in all groups by day 290, at which point all participants (20 of 20 evaluable participants) still had detectable IgG. …”
  20. 1860